Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2018

View Archived Issues

Predicting chemotherapy synergies

Repair cells can make things worse in neuromuscular disease

New arthritis severity gene id'd

Mortalin Kombat: Lysosomal inhibitor findings have cancer therapy implications

Award for Logic Biosciences' LBS-101 for oral mucositis

Mouse model reveals role of amylin signaling in POMC neurons in food intake, energy metabolism

Circadian regulation through MTNR1A contributes to the pathological cascade of Alzheimer's disease

SliC, a lysozyme-binding lipoprotein of N. gonorrhoeae with a key role during host colonization

Gut microbiota-derived metabolite TMAO found elevated in patients with Alzheimer's disease

ABL Bio and I-Mab enter immuno-oncology partnering agreement

Rxulti approved in E.U. for schizophrenia

European Commission approves Pfizer trastuzumab biosimilar Trazimera

Purdue completes phase Ib study of small molecule for insomnia associated with alcohol cessation

Myalepta approved for lipodystrophy in E.U.

Asterias releases Cohort 3 and 4 data from phase I/IIa SCiStar trial in severe spinal cord injury

European Commission approves Xeljanz for ulcerative colitis

Neuralstem begins phase II study of NSI-566 for ischemic stroke

NeuroActiva presents phase I data for NA-831 for Alzheimer's disease

New kinase inhibitors developed at IMPACT Therapeutics

Enanta Pharmaceuticals identifies respiratory syncytial virus inhibitors

ViiV Healthcare UK patents HIV integrase inhibitors

TGF-beta receptor type-1/2 inhibitors discovered at Bristol-Myers Squibb

Renji Hospital synthesizes aaptamine alkaloid derivatives

New phase I trial explores use of CERC-301 for neurogenic orthostatic hypotension in Parkinson's

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...